Klinik und Poliklinik für Geburtshilfe und Frauengesundheit
Klinikum / Johannes Gutenberg-Universität Mainz
Fasching, Peter A.; Brucker, Cosima; Decker, Thomas et al.
Progression-free survival and patient-reported outcomes in HR+, HER2-ABC patients treated with first-line ribociclib plus endocrine therapy (ET) or ET monotherapy or chemotherapy in real world setting: 5th interim analysis of RIBANNACANCER RESEARCH. Bd. 83. H. 5. 2023
Bossart, M.; Plett, H.; Kraemer, B. et al.
Psychological distress and its influencing factors in survivors of malignant ovarian germ cell and sex-cord stromal tumors & mdash;an analysis of the AGO-CORSET T databaseONKOLOGIE. 2023
Theis, S.; Baumgartner, S. J.; Janka, H. et al.
Quality of life in menopausal women in the workplace - a systematic reviewCLIMACTERIC. Bd. 26. H. 2. 2023 S. 80-87
Decker, Thomas; Brucker, Cosima; Engel, Anne et al.
Real-world efficacy of ribociclib (RIB) plus aromatase inhibitor (AI)/fulvestrant (FUL), or endocrine monotherapy (ET), or chemotherapy (CT) as first-line (1L) treatment (tx) in elderly patients (pts; > 75 years) with hormone receptor-positive (HR plus ), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC): Results of fifth interim analysis (IA) from RIBANNAJOURNAL OF CLINICAL ONCOLOGY. Bd. 41. H. 16. 2023
Krajnak, Slavomir; Krajnakova, Jana; Anic, Katharina et al.
Real-world experience of metronomic chemotherapy in metastatic breast cancer: results of a retrospective unicenter studyBREAST CARE. 2023
Jackisch, Christian; Brucker, Cosima; Decker, Thomas et al.
RIBANNA 5th interim analysis: Matched-pair analysis of progression-free survival (PFS) across treatment cohorts and comparison of frontline ribociclib plus endocrine therapy PFS data from RIBANNA vs MONALEESA trials, in HR+, HER2-ABCCANCER RESEARCH. Bd. 83. H. 5. 2023
Harbeck, N.; Fasching, P. A.; Wuerstlein, R. et al.
Significantly longer time to deterioration of quality of life due to CANKADO PRO-React eHealth support in HRD HER2L metastatic breast cancer patients receiving palbociclib and endocrine therapy: primary outcome analysis of the multicenter randomized AGO-B WSG PreCycle trialANNALS OF ONCOLOGY. Bd. 34. H. 8. 2023 S. 660-669
Hamoud, Bashar Haj; Kasoha, Mariz; Sillem, Martin et al.
Sonographic features of adenomyosis correlated with clinical symptoms and intraoperative findings: a case-control studyARCHIVES OF GYNECOLOGY AND OBSTETRICS. Bd. 307. H. 6. 2023 S. 1883-1889
Mueller, Volkmar; Fasching, Peter A.; Nabieva, Naiba et al.
Systemic Therapy of Premenopausal Patients with Early Stage Hormone Receptor-Positive, HER2-Negative Breast Cancer - Controversies and Standards in HealthcareGEBURTSHILFE UND FRAUENHEILKUNDE. Bd. 83. H. 6. 2023 S. 673-685
Schmidt, M; Loibl, S
Systemische Therapie bei endokrin empfindlichen KarzinomenUntch, Harbeck, Thomssen, Lüftner (Hrsg). Colloquium Senologie. München: Lukon 2023